Patients with B-ALL who are resistant to or relapse after CD19-targeted immunotherapies have few treatment options, however CARs targeting CD22 have shown promising efficacy and safety in early phase trials for several B cell cancers [71]. Here, CD19 is linked to acute lymphoblastic leukemia.